Albuterol/Budesonide Reduces Risk of Exacerbation in People with Intermittent, Mild-Persistent Asthma
Albuterol/budesonide (Airsupra), the inhaled anti-inflammatory asthma rescue medication from AstraZeneca, was associated with statistically significant and clinically meaningful reductions in the risk of severe disease exacerbations among individuals …